share_log

Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

Benzinga ·  Sep 7, 2023 21:21

Cantor Fitzgerald analyst Charles Duncan reiterates Vaxart (NASDAQ:VXRT) with a Overweight and maintains $4 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment